BBIO

Bullish

Encaleret NDA, Acoramidis Progress, and Buyback Could Be A Game Changer For BridgeBio (BBIO)

BridgeBio Pharma (BBIO) recently announced significant clinical and regulatory advancements, including an FDA submission for encaleret in ADH1 and fur...

Simply Wall Street 1 week ago 0

Bullish

Rare calcium disorder treatment encaleret heads to FDA review

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1...

Stock Titan 1 week ago 0